B. Metzler seel. Sohn & Co. AG Raises Stake in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in Ultragenyx Pharmaceutical by 94.3%, purchasing an additional 14,581 shares, bringing its total holdings to 30,038 shares valued at approximately $1.09 million.
• Institutional investors own 97.67% of Ultragenyx's stock, indicating strong institutional support for the company amidst ongoing share purchases and adjustments.
• Despite recent changes in stock price targets from several analysts, Ultragenyx Pharmaceutical maintains a "Moderate Buy" consensus rating with a target price averaging $81.50, reflecting investor optimism about future performance.

B. Metzler seel. Sohn & Co. AG grew its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 94.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,038 shares of the biopharmaceutical company's stock after acquiring an additional 14,581 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Ultragenyx Pharmaceutical were worth $1,088,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of RARE. Raymond James Financial Inc. bought a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $916,000. Stifel Financial Corp grew its holdings in Ultragenyx Pharmaceutical by 13.5% during the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after buying an additional 2,835 shares in the last quarter. Northern Trust Corp grew its holdings in Ultragenyx Pharmaceutical by 11.8% during the fourth quarter. Northern Trust Corp now owns 528,965 shares of the biopharmaceutical company's stock worth $22,254,000 after buying an additional 55,641 shares in the last quarter. AXA S.A. grew its holdings in Ultragenyx Pharmaceutical by 7.3% during the fourth quarter. AXA S.A. now owns 456,588 shares of the biopharmaceutical company's stock worth $19,209,000 after buying an additional 31,198 shares in the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in Ultragenyx Pharmaceutical by 23.1% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after buying an additional 269,733 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wedbush decreased their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Guggenheim reiterated a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. William Blair assumed coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target for the company. Morgan Stanley decreased their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, July 14th. Finally, Canaccord Genuity Group cut their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Eleven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE traded up $2.07 during trading on Tuesday, reaching $32.03. 2,011,501 shares of the stock traded hands, compared to its average volume of 1,389,699. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37. The company has a 50-day moving average of $30.73 and a 200-day moving average of $35.04. The stock has a market capitalization of $3.09 billion, a P/E ratio of -5.79 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. During the same quarter in the prior year, the firm earned ($1.52) EPS. The business's revenue for the quarter was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.